Source:http://linkedlifedata.com/resource/pubmed/id/11238096
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2001-3-12
|
| pubmed:abstractText |
Severe T-cell immunodeficiency after solid organ or bone marrow transplantation may result in the uncontrolled outgrowth of latently Epstein-Barr virus-infected B cells, leading to B-lymphoproliferative disorder (BLPD). Given the potentially important pathogenic role of IL-6 in BLPD, it was tested whether the in vivo neutralization of IL-6 by a monoclonal anti-IL-6 antibody could contribute to the control of BLPD. Safety and efficacy were assessed in 12 recipients of transplanted organs who had BLPD refractory to the reduction of immunosuppression over 8 days. Five patients received 0.4 mg/kg per day. The next 7 patients received 0.8 mg/kg per day. Treatment was scheduled to last 15 days. It was completed in 10 patients, and in the other 2 patients was discontinued early (days 10 and 13, respectively) because of disease progression. Treatment tolerance was good, and no major side effects were observed. High C-reactive protein levels were found in 9 patients before treatment but were normalized under treatment in all patients, demonstrating efficient IL-6 neutralization. Complete remission (CR) was observed in 5 patients and partial remission (PR) in 3 patients. Relapse was observed in 1 of these 8 patients in whom remission was observed. This relapse was unresponsive to treatment. Disease was stable in 1 patient, but it progressed in 3 patients. Seven patients are alive and well. Two patients died because of disease progression, and 3 patients died while in CR (chronic rejection in 2 patients and BLPD sequelae in 1 patient). These data suggest that the anti-IL-6 antibody is safe and should be further explored in the treatment of BLPD.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AchkarAA,
pubmed-author:BauwensMM,
pubmed-author:DebrayDD,
pubmed-author:DelwailVV,
pubmed-author:DurandyAA,
pubmed-author:DuvouxCC,
pubmed-author:FischerAA,
pubmed-author:HaddadEE,
pubmed-author:HubertPP,
pubmed-author:Hurault de LignyBB,
pubmed-author:LeblondVV,
pubmed-author:PaczesnySS,
pubmed-author:SeigneurinJ MJM,
pubmed-author:SternMM,
pubmed-author:WijdenesJJ
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1590-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11238096-Adolescent,
pubmed-meshheading:11238096-Adult,
pubmed-meshheading:11238096-Antibodies, Monoclonal,
pubmed-meshheading:11238096-Antibodies, Viral,
pubmed-meshheading:11238096-B-Lymphocytes,
pubmed-meshheading:11238096-C-Reactive Protein,
pubmed-meshheading:11238096-Child,
pubmed-meshheading:11238096-Child, Preschool,
pubmed-meshheading:11238096-Female,
pubmed-meshheading:11238096-Herpesvirus 4, Human,
pubmed-meshheading:11238096-Humans,
pubmed-meshheading:11238096-Infant,
pubmed-meshheading:11238096-Interleukin-6,
pubmed-meshheading:11238096-Lymphoproliferative Disorders,
pubmed-meshheading:11238096-Male,
pubmed-meshheading:11238096-Middle Aged,
pubmed-meshheading:11238096-Therapeutic Equivalency,
pubmed-meshheading:11238096-Tissue Transplantation,
pubmed-meshheading:11238096-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
|
| pubmed:affiliation |
Unité d'Immunologie et d'Hématologie Pédiatriques, Service de Réanimation Pédiatrique and INSERM U429, Hôpital Necker Enfants-Malades, Paris, France. elie.haddad@rdb.ap-hop-paris.fr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|